Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 5/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.42 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | CBFB | Q13951 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 4/20 | 0.39 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.38 |
| ▸ | SMAD2 | Q15796 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23418795 | 0.85 | TNIK (0.41) | TGFBR1MAPK14TNIKNPC1KDM4E | |
| SCHEMBL25822608 | 0.85 | IDO1 (0.45) | TGFBR1MAPK14TNIKNPC1KDM4E | |
| SCHEMBL23408398 | 0.85 | TGFBR1 (0.45) | TGFBR1CYP1A2MAPK14TNIKIDO1 | |
| SCHEMBL23392259 | 0.84 | TGFBR1 (0.44) | TGFBR1MAPK14TNIKNPC1KDM4E | |
| SCHEMBL25822607 | 0.76 | NPC1 (0.42) | TGFBR1CYP1A2NPC1KDM4EMETAP2 | |
| SCHEMBL23392011 | 0.74 | TGFBR1 (0.43) | TGFBR1MAPK14TNIKBMPR1ASMAD2 | |
| SCHEMBL25085300 | 0.74 | TGFBR1 (0.44) | TGFBR1MAPK14TNIKIDO1BMPR1A | |
| SCHEMBL29796536 | 0.74 | TGFBR1 (0.43) | TGFBR1MAPK14TNIKIDO1BMPR1A | |
| SCHEMBL23389618 | 0.74 | TGFBR1 (0.43) | TGFBR1MAPK14TNIKIDO1BMPR1A | |
| SCHEMBL23408112 | 0.74 | TGFBR1 (0.43) | TGFBR1MAPK14TNIKIDO1BMPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | TGFBR1 211/4885CYP1A2 3997/4885MAPK14 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.